Claims
- 1. A composition comprising a purified or isolated peptide, said purified or isolated peptide
(a) consisting of an amino acid sequence selected from the group consisting of:
(i) a four to seven amino acid segment of the sequence of MTRVLQGVLPALPQVVC (SEQ ID NO:44); and (ii) a derivative of the segment of (a) having one or more conservative substitutions relative to the sequence of SEQ ID NO:44; and (b) exhibiting an immunoregulatory activity as determined by measuring its capability of modulating production of NO by a cell.
- 2. The composition of claim 1 wherein the amino acid segment includes a sequence
AAL AAQ AAG AAV wherein AAL is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Ala and Leu, wherein AAQ is a substituted or unsubstituted amino acid selected from the group consisting of Gln, Pro, and Ala, wherein AAG is a substituted or unsubstituted amino acid Gly, and wherein AAV is a substituted or unsubstituted non-polar amino acid selected from the group consisting of Val and Ala.
- 3. The composition of claim 2 wherein said purified or isolated peptide has no more than six amino acids.
- 4. The composition of claim 2 wherein said purified or isolated peptide is selected from the group consisting of LQGV (SEQ ID NO:1), AQGV (SEQ ID NO:2), LQGA (SEQ ID NO:19), LAGV (SEQ ID NO:26), and LPGC (SEQ ID NO:41).
- 5. The composition of claim 1 wherein the purified or isolated peptide is MTRV (SEQ ID NO:42) or QVVC (SEQ ID NO:43).
- 6. The composition of claim 1 wherein the purified or isolated peptide has six or seven amino acids and comprises a sequence
AAV AAL Pro Arg AAL2 AAP wherein AAV is substituted or unsubstituted Val or Ala, wherein AAL and AAL2 are independently selected from substituted or unsubstituted Lys or Ala, and wherein AAP is a substituted or unsubstituted Pro or Ala.
- 7. The composition of claim 6 wherein the purified or isolated peptide consists of a sequence selected from the group consisting of VLPALP (SEQ ID NO:3), ALPALP (SEQ ID NO:21), VAPALP (SEQ ID NO:22), ALPALPQ (SEQ ID NO:23), VLPAAPQ (SEQ ID NO:24), VLPALAQ (SEQ ID NO:25), VLPALA (SEQ ID NO:28), VLPALPQ (SEQ ID NO:29), VLPALPA (SEQ ID NO:31), GVLPALP (SEQ ID NO:32), and VLAALP (SEQ ID NO: 117), or an acid addition salt of any thereof.
- 8. A composition including a purified or isolated oligopeptide having no more than eight amino acids, and including an amino acid sequence consisting of:
AAL AAQ AAG AAV wherein AAL is a substituted or unsubstituted amino acid selected from the group of amino acids consisting of Ala, Leu, and Met, wherein AAQ is a substituted or unsubstituted amino acid selected from the group of amino acids consisting of Gln, Thr, Ala, and Pro, wherein AAG is substituted or unsubstituted Gly or Arg, and wherein AAV is a substituted or unsubstituted amino acid selected from the group of amino acids consisting of Cys, Ala, and Val; said oligopeptide characterized in having immunoregulatory activity as determined by: measuring the oligopeptide's ability to modulate production of NO by a cell.
- 9. The composition of claim 8 wherein the sequence is selected from the group consisting of Leu Gln Gly Val (SEQ ID NO:1), Ala Gln Gly Val (SEQ ID NO:2), Leu Gln Gly Ala (SEQ ID NO:19), Leu Ala Gly Val (SEQ ID NO:26), Leu Pro Gly Cys (SEQ ID NO:41), and Met Thr Arg Val (SEQ ID NO:42).
- 10. The composition of claim 9 wherein the sequence is SEQ ID NO: 1.
- 11. The composition of claim 9 wherein the sequence is SEQ ID NO:2.
- 12. The composition of claim 9 wherein the sequence is SEQ ID NO: 19.
- 13. The composition of claim 9 wherein the sequence is SEQ ID NO:26.
- 14. The composition of claim 9 wherein the sequence is SEQ ID NO:41.
- 15. The composition of claim 9 wherein the sequence is SEQ ID NO:42.
- 16. A pharmaceutical composition comprising a purified or isolated peptide, said purified or isolated peptide
(a) consisting of an amino acid sequence selected from the group consisting of:
(i) a four to seven amino acid segment of the sequence of MTRVLQGVLPALPQVVC (SEQ ID NO:44); and (ii) a derivative of the segment of (a) having one or more conservative substitutions relative to the sequence of SEQ ID NO:44; and (b) exhibiting an immunoregulatory activity as determined by measuring the amino acid sequence's ability to modulate production of NO by a cell.
- 17. The pharmaceutical composition of claim 16 wherein the purified or isolated peptide is selected from the group selected from the group consisting of LQGV (SEQ ID NO: 1), AQGV (SEQ ID NO:2), VLPALP (SEQ ID NO:3), LQGA (SEQ ID NO:19), ALPALP (SEQ ID NO:21), VAPALP (SEQ ID NO:22), ALPALPQ (SEQ ID NO:23), VLPAAPQ (SEQ ID NO:24), VLPALAQ (SEQ ID NO:25), LAGV (SEQ ID NO:26), VLPALA (SEQ ID NO:28), VLPALPQ (SEQ ID NO:29), VLPALPA (SEQ ID NO:31), and GVLPALP (SEQ ID NO:32), LPGC (SEQ ID NO:41), MTRV (SEQ ID NO:42), QVVC (SEQ ID NO:43), VLAALP (SEQ ID NO: 117), and combinations of any thereof, presented in a pharmaceutically acceptable form for administration to a human.
- 18. A composition comprising a purified or isolated peptide consisting of GVLPALPQ (SEQ ID NO:33).
- 19. A compositon comprising a purified or isolated peptide selected from the group consisting of AQG, MTR, VVC, and mixtures thereof.
- 20. A composition comprising one or more purified or isolated peptides of the sequences LQGV (SEQ ID NO:1), AQGV (SEQ ID NO:2), VLPALP (SEQ ID NO:3), LQGA (SEQ ID NO:19), ALPALP (SEQ ID NO:21), VAPALP (SEQ ID NO:22), ALPALPQ (SEQ ID NO:23), VLPAAPQ (SEQ ID NO:24), VLPALAQ (SEQ ID NO:25), LAGV (SEQ ID NO:26), VLPALA (SEQ ID NO:28), VLPALPQ (SEQ ID NO:29), VLPALPA (SEQ ID NO:31), and GVLPALP (SEQ ID NO:32), LPGC (SEQ ID NO:41), MTRV (SEQ ID NO:42), QVVC (SEQ ID NO:43), VLAALP (SEQ ID NO:117), AQG, MTR, or VVC.
- 21. A composition comprising a purified or isolated peptide consisting of sequence LQG in an amount sufficient to exhibit an immunoregulatory activity as determined by measuring the sequence LQG's ability to modulate production of NO by a cell.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation in part of U.S. Ser. No. 10/028,075, filed Dec. 21, 2001, a continuation of U.S. Ser. No. 10/262,522, filed Sep. 30, 2002, which is a continuation of International Application No. PCT/NL01/00259, designating the United States of America published in English as PCT International Publication No. WO 01/72831 A2 filed Mar. 3, 2001, and a continuation in part of International Application No. PCT/NL02/00639, designating the United States of America and published on Apr. 10, 2003 in English as PCT Internatinal Publication No. WO 03/029292 A2, the contents of all of each of which are incorporated by this reference.
Continuations (2)
|
Number |
Date |
Country |
Parent |
10262522 |
Sep 2002 |
US |
Child |
10753510 |
Jan 2004 |
US |
Parent |
PCT/NL01/00259 |
Mar 2001 |
US |
Child |
10262522 |
Sep 2002 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
10028075 |
Dec 2001 |
US |
Child |
10753510 |
Jan 2004 |
US |
Parent |
PCT/NL02/00639 |
Apr 2003 |
US |
Child |
10753510 |
Jan 2004 |
US |